Business Wire

Omada Enables Advanced Governance Controls in Microsoft Azure Active Directory Premium


Omada, the market-leading provider of solutions for advanced identity management and access governance, today announces a strategic alliance with Microsoft. The alliance is an expansion of the long-term relationship between the two companies. At the center of the solution is the seamless integration of Omada’s Identity governance platform with Microsoft Azure Active Directory Premium. Built on Azure, to govern access across hybrid environments. The solution provides customers with advanced access governance controls across all enterprise systems - on-premise and in the cloud.

The integration offers comprehensive governance features, allowing modern enterprises to ensure security, compliance and efficiency. With a 360-degree view of all access rights for all users, enterprises have the full overview and control of employees, contractors, partners, and their access, across hybrid environments.

Alex Simons, Director, Product Management, Microsoft Identity Division at Microsoft Corp. says,

“Our expanded integration with Omada is an important step in our journey to cover all dimensions of identity-driven security. Omada’s platform is built on Microsoft technology and is the perfect fit for Azure Active Directory Premium. The two solutions combined give customers a future-proof, and easy-to-use, identity management and access governance solution across on-premise and cloud.”

Creating measurable business value

Omada’s solution provides features such as user-friendly self-service access request portal, automation of access certification, and automation of the access review processes together with automated audit and compliance reporting.

“Since Omada was founded almost two decades ago, one of the key insights from our customer and partner engagements that has especially stood out has been: we help them do more with identity and create measurable business value,” says Morten Boel Sigurdsson, CEO and founder of Omada. “We are thrilled about announcing this strategic alliance between Microsoft and Omada, which takes our relationship to a new level and enables us to deliver even more value to our customers.”

Covering security, compliance and efficiency needs

The Omada Identity Platform is acknowledged for its strong identity governance capabilities by customers, partners, and leading analysts. When combined with the secure access and risk-based identity protection of Microsoft Azure Active Directory Premium, the solution enables customers to focus on their business by fully covering some of their most demanding security, compliance, and efficiency needs.

The strategic alliance enables organizations to enhance Microsoft’s access management and identity protection services with Omada’s identity governance and administration platform, built on Microsoft technologies. This means, that customers can use their already existing Microsoft expertise in the organization.

Do more with identity

At Omada, we are focused on using identity to create measurable business value –from IT and HR to Marketing and Sales. Identity, managed the Omada way, simultaneously improves security, efficiency, cost control, and regulatory compliance throughout any organization.

And, it can do even more. Identity can accelerate digital transformations, smooth M&A integration, and enable deeper relationships with suppliers and customers. Few technologies have the potential to impact so much. Belief in this essential role of identity unites our organization, fuels our innovation, and strengthens our collaboration with partners.

We’ve pioneered many of the best practices in use today, and are passionate about taking identity management even further. We are committed to using identity to create business value.

About Omada

Established in 2000, Omada has operations in North America and Europe, delivering solutions directly and via a network of skilled partners and system integrators.

Omada’s Identity Platform is recognized by Gartner in the ‘Critical Capabilities report for IGA’, where Omada received the 3rd highest scores in two out of four use cases.

Omada is a Microsoft Gold Certified Partner and three times global Microsoft Award winner of the Microsoft Identity & Secure Access Award, recognized for providing advanced identity and access governance scenarios utilizing the Microsoft stack. The Omada Identity Platform utilizes Microsoft technologies to provide enterprise-ready identity solutions across heterogeneous IT platforms, supporting hybrid scenarios. Omada’s certified solution is based on well proven components in the Microsoft technology stack like Windows Server, the .NET framework, SQL Server and BI services for enhanced analytics experiences.


Contact information

Anne Dorthe H. Gyldenkærne, Vice President Global Marketing & Communication
T: +45 7025 0069
M: +45 2018 1881

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on